SCHEMBL1151641

SCHEMBL1151641

O=C(Cl)OC(=O)c1ccccc1

nearest known ligand 0.58

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
LMNA P02545 2/20 0.58
F2 P00734 1/20 0.58
TSHR P16473 5/20 0.54
TDP1 Q9NUW8 3/20 0.48
TP53 P04637 1/20 0.48
ALDH1A1 P00352 6/20 0.47
KMT2A Q03164 3/20 0.47
MAPT P10636 2/20 0.47
MAPK1 P28482 2/20 0.47
HIF1A Q16665 2/20 0.47
POLB P06746 1/20 0.47
SLC6A2 P23975 1/20 0.47
SLC6A3 Q01959 1/20 0.47
CES2 O00748 2/20 0.46
CES1 P23141 2/20 0.46
DAO P14920 1/20 0.46
NAPRT Q6XQN6 1/20 0.46
SMN1; SMN2 Q16637 1/20 0.45
HSD17B10 Q99714 1/20 0.45
TRPA1 O75762 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Methane SCHEMBL5609245 0.98 LMNA (0.56) LMNAF2TSHRTDP1TP53
SCHEMBL6656414 0.87 CA1 (0.41) LMNAF2TSHRTDP1TP53
SCHEMBL8508528 0.86 LMNA (0.58) LMNAF2TSHRTDP1TP53
Benzene SCHEMBL27793442 0.85 LMNA (0.70) LMNAF2TSHRTDP1TP53
SCHEMBL52413 0.85 LMNA (0.70) LMNAF2TSHRTDP1TP53
Hydrogen Peroxide SCHEMBL27952375 0.85 LMNA (0.70) LMNAF2TSHRTDP1TP53
SCHEMBL6656417 0.84 TSHR (0.55) TSHRTP53ALDH1A1MAPTCES2
Benzoyl Chloride SCHEMBL28645107 0.84 LMNA (0.56) LMNAF2TSHRTDP1TP53
SCHEMBL1534569 0.82 LMNA (0.67) LMNAF2TSHRTDP1TP53
SCHEMBL2591454 0.82 LMNA (0.67) LMNAF2TSHRTDP1TP53

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 195 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2017271-A1 Process for the preparation of escitalopram Aurobindo Pharma Limited (IN) 2009-01-21 EP claimed
US-20230365559-A1 NOVEL AMINOPYRIDINES AND THEIR USE IN TREATING CANCER AUCKLAND UNISERVICES LIMITED (NZ) 2023-11-16 US disclosed
CN-116669725-A Novel aminopyridine and use thereof in the treatment of cancer 奥克兰联合服务有限公司 2023-08-29 CN disclosed
EP-4217357-A1 NOVEL AMINOPYRIDINES AND THEIR USE IN TREATING CANCER Auckland Uniservices Limited (NZ) 2023-08-02 EP disclosed
WO-2022064430-A1 NOVEL AMINOPYRIDINES AND THEIR USE IN TREATING CANCER AUCKLAND UNISERVICES LIMITED (NZ) 2022-03-31 WO disclosed
WO-2021013163-A1 HISTONE DEACETYLASE 6 INHIBITORS AND METHOD FOR TREATING NEUROPATHIC PAIN TAIPEI MEDICAL UNIVERSITY (CN) 2021-01-28 WO disclosed
CN-106232214-B Composite polyamide membrane post-treated with nitrous acid 陶氏环球技术有限责任公司 2021-01-15 CN disclosed
CN-105848758-B Separation of hydrocarbons from aqueous mixtures using fouling resistant reverse osmosis membranes 陶氏环球技术有限责任公司 2020-01-17 CN disclosed
CN-110167982-A The manufacturing method of block copolymer and block copolymer 电化株式会社 2019-08-23 CN disclosed
EP-3108900-B1 PROTOTYPE SYSTEMS OF THERANOSTIC BIOMARKERS FOR IN VIVO MOLECULAR MANAGEMENT OF CANCER EPOS IASIS RES AND DEVELOPMENT LTD (CY) 2019-04-24 EP disclosed
EP-0434708-A1 PROCESS FOR PRODUCING DIPEPTIDES FROM NON-PROTEINOGENIC AMINO ACIDS WITH TERMINAL NITROGEN ATOMS. BASF AG (DE) 1991-07-03 EP disclosed
WO-1990003387-A1 PROCESS FOR PRODUCING DIPEPTIDES FROM NON-PROTEINOGENIC AMINO ACIDS WITH TERMINAL NITROGEN ATOMS BASF AKTIENGESELLSCHAFT (DE) 1990-04-05 WO disclosed
US-4665171-A CARBACEPHALOSPORINS HARVARD UNIVERSITY (US) 1987-05-12 US disclosed
EP-0120728-A1 Thiazine and thiazepine containing compounds E.R. Squibb & Sons, Inc. (US) 1984-10-03 EP disclosed
US-4460579-A HYPOTENSIVE AGENTS, ANGIOTENSIN CONVERTING ENZYME INHIBITORS E. R. SQUIBB & SONS, INC. (US) 1984-07-17 US disclosed
EP-0000473-A1 Process for preparing aminoglycoside derivatives, novel derivatives obtained and pharmaceutical compositions containing such derivatives Technobiotic Ltd. (CH) 1979-02-07 EP disclosed
US-4138397-A BACTERICIDES RICHARDSON-MERRELL INC. (US) 1979-02-06 US disclosed
US-4053591-A 5-DEOXY-4,6-DI-O-(AMINOGLYCOSYL)-1,3-DIAMINOCYCLITOLS, METHODS FOR THEIR MANUFACTURE, METHOD FOR THEIR USE AS ANTIBACTERIAL AGENTS AND COMPOSITIONS USEFUL THEREFOR SCHERING CORPORATION (US) 1977-10-11 US disclosed
US-4016146-A Phenethylamine antigenic conjugates, their preparation, antibodies, and use BIOLOGICAL DEVELOPMENTS, INC. (US) 1977-04-05 US disclosed
US-3996344-A Phenethylamine antigenic conjugates, their preparation, antibodies and use BIOLOGICAL DEVELOPMENTS, INC. (US) 1976-12-07 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230365559-A1 NOVEL AMINOPYRIDINES AND THEIR USE IN TREATING CANCER DCK, DTYMK, TYMP LMNA 1848/4885F2 4154/4885TSHR 4122/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.